Last reviewed · How we verify
Bacteriology
Bacteriology is a Biologic drug developed by Tejs Ehlers Klug. It is currently in Phase 2 development.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Bacteriology |
|---|---|
| Sponsor | Tejs Ehlers Klug |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pulmonary Diffusion of Antibiotics in Patients Admitted for ARDS Following SARS-CoV-2 Pneumonia (NA)
- Interest of the Detection of Hyper-virulent Clone ST17 of Group B Strep (GBS) for the Prevention of Neonatal GBS Meningitis (NA)
- Cell Content of Sputum Induced by Hypertonic Saline in Adolescents With Cystic Fibrosis (NA)
- Immunity After Cochlear Implantation and Perilymph Molecular Profiles in Sensorineural Hearing Loss (NA)
- Clinical Grade MIS Device for Cervical Assessment to Predict Preterm Birth (NA)
- Bacteriology of sUrGical Site INfection Following Surgery for Intestinal Failure
- The Microbiology of Pleural Infection
- Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bacteriology CI brief — competitive landscape report
- Bacteriology updates RSS · CI watch RSS
- Tejs Ehlers Klug portfolio CI
Frequently asked questions about Bacteriology
What is Bacteriology?
Who makes Bacteriology?
What development phase is Bacteriology in?
Related
- Manufacturer: Tejs Ehlers Klug — full pipeline
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing